Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 18 of 18 results for pazopanib

  1. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

    Technology appraisal guidance
    Discontinued

  2. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued [GID-TAG398]

    Technology appraisal guidance
    Discontinued

  3. Nivolumab for previously treated advanced renal cell carcinoma (TA417)

    Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA417